What is CJC-1295 and how does it work in research?

CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) studied in laboratory settings for its ability to bind GHRH receptors in the anterior pituitary. In research models, it activates cAMP signaling pathways, increases growth hormone pulse amplitude, and influences downstream IGF-1 signaling. It is strictly a research compound used to study endocrine and metabolic signaling frameworks, not intended for human use.

What is the difference between CJC-1295 DAC and No DAC?

CJC-1295 DAC includes a Drug Affinity Complex modification enabling albumin binding, extending its half-life to approximately 6–8 days in research contexts, supporting sustained GH release models. The No DAC version, also called MOD GRF 1-29, has a much shorter half-life measured in minutes to hours, making it relevant for studying pulse-like, physiologic GH stimulation patterns in laboratory experimental frameworks.

What is the half-life of CJC-1295 in research models?

In research discussions, CJC-1295 DAC is described as significantly longer acting due to its albumin-binding Drug Affinity Complex, with a reported half-life of roughly 6–8 days under experimental conditions. The No DAC variant is considerably shorter acting, often described in terms of minutes to hours, making it more suited for studying pulsatile growth hormone release patterns in laboratory models.

How does CJC-1295 differ from Sermorelin in peptide research?

Both CJC-1295 and Sermorelin are discussed as GHRH receptor–targeting peptides in research settings, but they differ structurally. Sermorelin is a shorter GHRH fragment, while CJC-1295 is a modified analog engineered for greater stability and extended half-life. Research models use these distinctions to study differences in receptor binding duration, GH pulse dynamics, and pharmacokinetic behavior within endocrine signaling frameworks.

What is the difference between CJC-1295 and Ipamorelin in GH axis research?

In research models, CJC-1295 acts through the GHRH receptor to stimulate pituitary growth hormone release, while Ipamorelin acts through the ghrelin receptor (GHS-R1a) to influence GH pulse frequency. Because these pathways are mechanistically distinct, researchers often examine them together to study multi-pathway growth hormone axis signaling, GH pulse amplitude and frequency dynamics, and combined endocrine signaling interactions in laboratory settings.

Does CJC-1295 influence IGF-1 in laboratory research models?

CJC-1295 is frequently studied in research contexts because growth hormone signaling stimulated through the GHRH receptor can influence downstream IGF-1 pathways. Whether measurable IGF-1 changes occur depends on the specific research model, experimental duration, and study endpoints. This is an area of ongoing laboratory investigation. All findings are limited to preclinical research contexts; no clinical or human-use claims are made.

Introduction

CJC-1295 is a synthetic growth hormone–releasing hormone (GHRH) analog commonly studied in laboratory settings for its role in stimulating endogenous growth hormone (GH) release. Within peptide research communities, it is often evaluated for its long-acting pharmacokinetic profile, pulsatile GH stimulation patterns, and potential synergy with GHRP compounds such as Ipamorelin.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

IGF — 1 LR3 1MG

IGF-1 LR3 1MG — Research-Grade Reference Material IGF-1 LR3 1MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$65.00 ($48.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Researchers frequently search:

What is CJC-1295?
What does CJC-1295 do?
CJC-1295 DAC vs No DAC?
CJC-1295 vs Ipamorelin?
Is CJC-1295 a growth hormone peptide?

This guide breaks down the science.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

IGF — 1 LR3 1MG

$65.00 ($48.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH) commonly studied in laboratory settings for its ability to stimulate endogenous growth hormone (GH) release through the GHRH receptor. It’s frequently discussed in endocrine and metabolic research models focused on GH pulsatility and downstream signaling (including IGF-1 pathways).

What does CJC-1295 do in research models?

In research contexts, CJC-1295 is studied for its effect on growth hormone pulse amplitude and endocrine signaling dynamics. Researchers often explore how it influences GH release patterns, feedback regulation, and downstream pathways associated with metabolism, tissue remodeling environments, and growth-related signaling frameworks.

What is the difference between CJC-1295 DAC vs No DAC?

CJC-1295 DAC includes a Drug Affinity Complex modification designed to extend the peptide’s half-life by increasing albumin binding in experimental settings. “No DAC” versions (often discussed as MOD GRF 1-29) are shorter acting and more commonly associated with pulse-like GH stimulation models. The difference is primarily duration and pharmacokinetic behavior in research frameworks.

Is CJC-1295 the same as Sermorelin?

No. Sermorelin is a shorter GHRH fragment commonly used in research discussions, while CJC-1295 is a modified GHRH analog designed for greater stability. Both are discussed in GHRH receptor signaling research, but they differ in sequence design and expected duration in experimental models.

Does CJC-1295 increase IGF-1?

CJC-1295 is frequently studied because GH signaling can influence IGF-1 pathways downstream. Whether IGF-1 changes occur and to what degree depends on the research model, study duration, and experimental endpoints. This content is educational and does not imply clinical outcomes.

What is the half-life of CJC-1295?

Half-life varies by version. Research discussions often describe CJC-1295 DAC as longer acting due to albumin-binding behavior, while No DAC variants are typically discussed as shorter acting and more pulse-oriented. Exact half-life depends on formulation and experimental conditions.

CJC-1295 vs Ipamorelin: what’s the difference?

CJC-1295 acts through the GHRH receptor to stimulate pituitary GH release. Ipamorelin is commonly discussed as a ghrelin-receptor (GHS-R1a) agonist in research settings. Because these pathways are distinct, researchers often compare them or explore them together in GH axis signaling models.

Can CJC-1295 and Ipamorelin be studied together?

Some research frameworks explore both compounds because they act through different upstream mechanisms (GHRH receptor vs ghrelin receptor). Combined study designs may be used to examine GH pulse dynamics and multi-pathway endocrine signaling interactions, depending on the research goal.

Is CJC-1295 intended for human use?

No. CJC-1295 products are supplied for laboratory and analytical research use only and are not intended for human or veterinary use. This content is educational and does not provide medical advice.

What Is CJC-1295?

CJC-1295 is a modified analog of growth hormone–releasing hormone (GHRH). It was engineered to increase stability and prolong half-life compared to native GHRH.

Unlike direct growth hormone administration, CJC-1295 works upstream by stimulating the pituitary gland to release endogenous growth hormone.

In laboratory research models, this makes it useful for studying:

GH pulsatility
IGF-1 modulation
Metabolic signaling
Body composition models
Sleep-phase GH release patterns

Mechanism of Action: How CJC-1295 Works

CJC-1295 binds to GHRH receptors located in the anterior pituitary.

This activates:

cAMP signaling pathways
Increased growth hormone pulse amplitude
Downstream IGF-1 signaling

Instead of flooding the system with GH, CJC-1295 enhances the body’s own pulsatile release pattern — which is often a major research focus in endocrine physiology models.

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

CJC-1295 DAC vs No DAC

This is one of the most searched distinctions.

CJC-1295 DAC

DAC stands for Drug Affinity Complex.

The DAC modification allows the peptide to bind to albumin, dramatically increasing half-life (up to ~6–8 days in research contexts).

Research focus:

Sustained GH release
Reduced injection frequency models
Long-term IGF-1 elevation

CJC-1295 No DAC (MOD GRF 1-29)

The “No DAC” version is shorter acting.

Half-life is significantly shorter (minutes to hours), leading to:

More physiologic pulse-like GH stimulation
Closer mimicry of natural GHRH bursts
Often studied in combination protocols

CJC-1295 vs Ipamorelin

This comparison drives massive search volume.

CJC-1295:

Acts via GHRH receptor
Stimulates pituitary directly

Ipamorelin:

Acts via ghrelin receptor (GHS-R1a)
Mimics ghrelin-like signaling

When combined in research settings:

CJC-1295 amplifies GH signaling
Ipamorelin increases GH pulse frequency

The synergy model is frequently studied in growth hormone axis research.

Buy CJC 1295 (no DAC) 5mg / Ipamorelin 5mg Total 10MG

Buy CJC w/ DAC 5MG

Growth Hormone & IGF-1 Research Models

CJC-1295 is often studied in contexts involving:

Muscle protein synthesis pathways
Fat metabolism signaling
Sleep-phase GH release
Tissue repair models
Age-related GH decline

Because it stimulates endogenous production, it allows researchers to observe regulatory feedback mechanisms — something direct GH does not allow.

Why Researchers Study CJC-1295 Instead of Direct GH

Direct GH bypasses upstream regulation.

CJC-1295 allows investigation into:

Hypothalamic–pituitary axis dynamics
Feedback inhibition
Natural pulsatility patterns
IGF-1 downstream signaling

This makes it valuable in endocrine research environments.

CJC-1295 in Broader Peptide Stacks

CJC-1295 is often discussed alongside:

For researchers building multi-pathway models (recovery + growth + metabolism).

Common Search Questions About CJC-1295

what is cjc 1295 used for (research)
does cjc 1295 increase igf-1
cjc 1295 dac vs no dac difference
how does cjc 1295 work
cjc 1295 half life
cjc 1295 vs sermorelin

Research-Use Disclaimer

CJC-1295 products are supplied strictly for laboratory research and analytical use only. They are not intended for human consumption or clinical use.

Sources & Further Reading

Growth Hormone-Releasing Hormone Analog Research

PubMed: https://pubmed.ncbi.nlm.nih.gov/15085164

Long-Acting GHRH Analogs (DAC Studies)

PubMed: https://pubmed.ncbi.nlm.nih.gov/16469799

Growth Hormone Pulsatility and Regulation

NIH / NCBI: https://www.ncbi.nlm.nih.gov/books/NBK279083

CJC-1295 Explained: Mechanisms, DAC vs No DAC & Research Applications